Previous Article | Next Article 
Molecular and Cellular Biology, January 1999, p. 577-584, Vol. 19, No. 1
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Elevated Levels of a U4/U6.U5 snRNP-Associated
Protein, Spp381p, Rescue a Mutant Defective in Spliceosome
Maturation
Suzanne
Lybarger,
Kristopher
Beickman,
Vicky
Brown,
Neetu
Dembla-Rajpal,
Kristin
Morey,
Rebecca
Seipelt, and
Brian C.
Rymond*
T. H. Morgan School of Biological
Sciences and The Markey Cancer Center, University of Kentucky,
Lexington, Kentucky 40506-0225
Received 13 May 1998/Returned for modification 2 July 1998/Accepted 22 September 1998
 |
ABSTRACT |
U4 snRNA release from the spliceosome occurs through an essential
but ill-defined Prp38p-dependent step. Here we report the results of a
dosage suppressor screen to identify genes that contribute to
PRP38 function. Elevated expression of a previously
uncharacterized gene, SPP381, efficiently suppresses the
growth and splicing defects of a temperature-sensitive (Ts) mutant
prp38-1. This suppression is specific in that enhanced
SPP381 expression does not alter the abundance of
intronless RNA transcripts or suppress the Ts phenotypes of other
prp mutants. Since SPP381 does not suppress a
prp38::LEU2 null allele, it is clear that Spp381p
assists Prp38p in splicing but does not substitute for it. Yeast
SPP381 disruptants are severely growth impaired and
accumulate unspliced pre-mRNA. Immune precipitation studies show that,
like Prp38p, Spp381p is present in the U4/U6.U5 tri-snRNP particle.
Two-hybrid analyses support the view that the carboxyl half of Spp381p
directly interacts with the Prp38p protein. A putative PEST proteolysis
domain within Spp381p is dispensable for the Spp381p-Prp38p
interaction and for prp38-1 suppression but contributes to
Spp381p function in splicing. Curiously, in vitro, Spp381p may not be
needed for the chemistry of pre-mRNA splicing. Based on the in vivo and
in vitro results presented here, we propose that two small acidic
proteins without obvious RNA binding domains, Spp381p and Prp38p, act
in concert to promote U4/U5.U6 tri-snRNP function in the spliceosome cycle.
 |
INTRODUCTION |
Pre-mRNA splicing occurs through a
pair of transesterification reactions catalyzed by a complex enzyme,
the spliceosome (reviewed in references 19, 23, and
26). Each round of intron removal progresses through
an evolutionarily conserved cycle of subunit addition, catalysis, and
subunit release from the surface of the splicing substrate. The great
specificity of splicing is derived largely from the precise interaction
of requisite intron consensus sequences with the dynamic spliceosomal structure.
In vitro, ATP-independent interactions between the U1 small nuclear
ribonucleoprotein (snRNP) particle and the pre-mRNA 5' splice site and
branchpoint regions occur to form a complex resistant to competing
substrate challenge (reviewed in reference 34). This
structure, the commitment complex, stimulates the subsequent ATP-dependent addition of the U2 snRNP to the pre-mRNA branchpoint. The
resulting U1-U2-pre-mRNA prespliceosome is then bound by the U4/U6.U5
tri-snRNP particle to form the spliceosome. Before pre-mRNA 5' splice
site cleavage (chemical step 1 in splicing), the extensive U4/U6
intermolecular snRNA helices are unwound through a poorly understood
ATP-dependent maturation step. U4 snRNA may then be released from the
spliceosome (9, 18, 29), and pre-mRNA splicing progresses
(47).
The number of ATP hydrolysis events that occur in spliceosome assembly
is unknown. At least seven proteins with sequence similarity to a class
of RNA-dependent helicases interact with the splicing complex (the
DExD/H-box proteins, reviewed in references 8 and
38). It is generally believed that ATP hydrolysis by
the DExD/H-box proteins drive conformational changes within the
splicing complex, such as the resolution of certain temporally
restricted snRNA-snRNA and pre-mRNA-snRNA base pairing interactions
(1, 16, 17, 27, 37, 43, 46). Even though Prp38p, a
U4/U6.U5-specific protein, does not have a DExD/H-box motif, it is
required for the resolution of the U4/U6 helices within the spliceosome
(45). Prp38p likely functions indirectly in this process,
perhaps by facilitating substrate presentation or through the
recruitment or activation of a helicase activity.
In this study, we used the conditional lethal mutant prp38-1
to screen for spliceosomal factors that interact with Prp38p. Elevated
expression of the single gene SPP381 (for the suppressor of
prp38-1) was found to suppress the temperature-sensitive
growth and splicing defects of the prp38-1 mutant. The
genetic and biochemical data presented suggest that the
SPP381-mediated prp38-1 suppression occurs
through direct contact between the two gene products. Like Prp38p,
Spp381p is a small, acidic protein component of the U4/U6.U5 tri-snRNP
particle. Curiously, Spp381p contains a PEST proteolysis motif that
appears important for pre-mRNA splicing. This report identifies an
unusual new component of the splicing apparatus that functions in
concert with the Prp38p spliceosome maturation factor to support
cellular pre-mRNA processing.
 |
MATERIALS AND METHODS |
Yeast strains.
Yeast strains used were MGD353-46D
(MAT
leu2-3,112 trp1-289 ura3-52 his cyhr),
MGD353-13D (MATa leu2-3,112 trp1-289 ura3-52 arg4
ade2), MGD407 (MAT
/a leu2-3,112 trp1-289
ura3-52; diploid of MGD353-46D × MGD353-13D), ts192
(MAT
prp38-1 leu2-3,112 trp1-289 ura3-52 his
cyhr), YPB2 (MATa leu2-3,112
ade2-101 his3-200 lys2-801 trp1-901 ura3-52 gal4-542 gal80-538
LYS2::GAL1-HIS3 URA3::GAL-lacZ
canr), SUL1 [MATa
spp381::LEU2 leu2-3,112 trp1-289 ura3-52 pBM150
(GAL1::SPP381HA)], SUL2 [MAT
prp38-1 leu2-3,112 trp1-289 ura3-52 his YEplac112
(TRP1 SPP381)], SLU3 (MATa ura3-52 leu2-3,112 spp381::LEU2 his), KBY2 [MAT
prp38::LEU2 trp1-289 ura3-52 leu2-3,112 pYCplac22
(TRP1 PRP38HA)], SLY27 [MAT
leu2-3,112 trp1-289
ura3-52 arg4 prp39::LEU2 pYCplac22 (TRP1
PRP39HA)], and JXY6 [MATa
prp38::LEU2 trp1-289 ura3-52 leu2-3,112 ade2 YCplac22
(TRP1 prp38-2)].
Identification of suppressor plasmids.
Standard protocols
were used for yeast culture, transformation, sporulation, and tetrad
dissection (15). The YEp13-based yeast genomic library was
obtained from the American Type Culture Collection (ATCC stock no.
37323). Approximately 1 µg of the YEp13 library was used to transform
strains ts192. Suppressors were selected on synthetic medium lacking
leucine at 37°C for 48 h. Putative suppressor plasmids were
recovered from lysates (28) prepared from colony-purified
yeast. This DNA was amplified in Escherichia coli TG1 and
reintroduced into the ts192 yeast host to test for plasmid-linked
suppression. DNA sequence analysis on the recovered plasmids was
performed with primers that flank the YEp13 BamHI cloning
site (5'GCG CCG GTG ATG CCG GCC ACG AT3' and 5'CTA CTT GGA GCC ACT ATC
GAC TAC3'). A Southern blot of XbaI/PstI-digested plasmid DNA was hybridized with probes consisting of the
PRP38 and SPP381 open reading frames (ORFs)
in order to identify plasmids with related DNA inserts. The isolation
of mutant alleles prp38-1 and prp38-2 has been
described previously (5, 45).
Subcloning and gene disruption.
Plasmid pBM150
(SPP381HA) was created by placing the SPP381HA
ORF downstream of the GAL1 promoter of plasmid pBM150
(14). This was done by inserting an SPP381HA PCR
fragment flanked by BamHI (upstream primer, 5'TCC CAC
GGA TCC ATG AGT TTT AGA CAT TTC AAG AGG3' [the
BamHI site is underlined, and the translational initiation
codon is boldfaced]) and SalI (downstream primer, 5'TCC CAC
GTC GAC TTA AGC GTA GTC TGG AAC GTC GTA TGG GTA
TAT AAC CGA ATA TTC AGT TTC TTC3' [the SalI site is
underlined and the hemagglutinin {HA} epitope is boldfaced])
restriction sites into BamHI/SalI-digested pBM150
plasmid DNA. Protein sequence analysis for PEST elements was performed
with the public domain software available at
www.at.embnet.org/embnet/tools/bio/PESTfind.
Disruption of the SPP381 ORF was performed in two steps by
standard recombinant DNA techniques (36). First a 2.6-kbp
EcoRI fragment of library plasmid YEp13-7 was subcloned into
vector YEp112 to create the SPP381-bearing plasmid
YEplac112-7A. This plasmid was digested with BamHI and
BstEII to release SPP381 sequences from
261 to
+820 near the 3' end of the SPP381 coding sequence. This
sequence was replaced with a 315-bp
BamHI-BstEII-digested fragment created by PCR
that extends from the BamHI site to a novel
BstEII site introduced at position +42 by PCR (upstream primer, 5'ATA TTT ATA ACG CTA AGA TGA3'; downstream primer, 5'CCA CAC
GGT GAC CAG ATC TTG AGC TTG TGT CAA GTC TCC T3' [the
BstEII site is underlined]). The resulting construct,
spp381
42-820, removes all coding sequences between
positions 42 and 820 of the 876-nucleotide SPP381 ORF. The
1.6-kbp LEU2 gene was inserted by placing a 1.6-kbp
BamHI fragment from plasmid YDpL (4) into the
BglII site at the spp381
42-820 deletion
boundary. This plasmid was then cleaved with BamHI and
BstUI to release the spp381::LEU2 fragment for transformation into the diploid yeast strain MGD407. The
hemizygous disruptants were selected on medium lacking leucine. After
sporulation, yeast cells were dissected on 1% yeast extract-2% BactoPeptone (YP) agar with 2% glucose (15) and incubated
at 30°C. The presence of the correct genomic disruption in the
haploid offspring was confirmed by PCR with primers upstream (5'ATA TTT ATA ACG AGA TGA3') and downstream (5'GTA CTG TAT TTC TGC TAG ATT G3')
of the SPP381 gene. Parallel experiments were performed with the hemizygous spp381::LEU2 disruptant transformed
with pBM150 (GAL1::SPP381HA). In this case,
however, 2% galactose was used in the YP agar for yeast tetrad
dissection. Growth assays were performed on YP-glucose and YP-galactose
media, and MGD353-46D was used as the wild-type parent. The PEST
sequence deletion was introduced by PCR into the
GAL1::SPP381HA and YEplac112-7A backgrounds with
primers 5'CCT TTA CCG AGG CCA TTA TTT ATG3' and 5'TCC TGT ACC ATT TAA
AAT TTC GCC3'. Northern assays for pre-mRNA splicing were performed as
previously described (5). Ethidium bromide included in the
sample loading buffer allowed the stained rRNA bands to be used as
controls for equivalent sample loading, transfer efficiency, and RNA integrity.
Two-hybrid analysis.
The two-hybrid plasmids pACT and pAS2
have been described previously (24) (note that pAS2 was
previously referred to as pAS1). Two-hybrid constructs of
SPP381 were prepared as BamHI-BamHI (or BamHI-BglII) fragments inserted into the
BglII site of pACT and the BamHI site of pAS2.
BamHI (GGATCC) and BglII (AGATCT) restriction
sites were introduced by PCR and are underlined in the sequences
described. Upstream and downstream primers for full-length SPP381 fusion were 5'GGA TCC TAA TGA GTT TTA GAC
ATT TCA AGG3' and 5'GGA TCC TAA CTG AAA GGC ATG TGG GTT
TG3', respectively. The SPP381(1-145) construct
was prepared by using the upstream primer paired with the internal
primer 5'AGG ATC CAA CTA TTG ATT AGC TTT GTC GAT3'. The
SPP381(146-292) construct was prepared by
pairing the downstream primer with the internal primer 5'AGG ATC
CAA GTG GCA AAG AAC TAG GAA. The full-length PRP38
fusion, PRP38(1-242), was prepared similarly by
using the upstream primer 5'CTT AGA TCT GAC TAC AAT GGC TGT
CAA TG3' and the downstream primer 5'TTG GGA TCC TCG GGT
GAA ATT GCA AAT GAC3'. The internal primers 5'AGG ATC CAA TCA AGC AAT AAT ATA TTT CGA3' and 5'AGG ATC CAA TTG CAA CTG
GTT TAT GCG3' were used for PRP38(1-121) and
PRP38(122-242) amplification, respectively.
-Galactosidase assays were carried out as described previously
(15) except that the yeast cells were permeabilized by
immersion in liquid nitrogen for 1 min prior to the assay.
Yeast extracts, immune precipitation, and Western blotting.
Yeast extracts were prepared by the ground cell pellet method of Umen
and Guthrie (41). To prepare yeast extracts depleted of
Spp381HAp, a 10-ml saturated culture of strain SUL1 grown in YP-galactose was added to 2 liters of YP-glucose and grown at 30°C
for 17.5 h prior to harvest. Immune precipitations were carried out essentially as described previously (21). Twenty
microliters of yeast extract (at approximately 20 µg of protein per
µl of extract) was mixed with 40 µl of a 50% slurry of protein A+G
agarose (Oncogene, Inc.) bound with the HA.11 antibody (Babco) or with the mAb63 control antibody as described previously (25). To this mixture was added 3 µl of 100 mM dithiothreitol, 50 U of RNasin
(Promega), and HNT (20 mM HEPES [pH 7.9], 100 mM NaCl, 12.5 mM
MgCl2, 0.05% Triton X-100) to 150 µl. The tubes were
incubated with constant rotation at room temperature for 30 min. The
unbound extract was removed by centrifugation at 4,000 × g for 1 min. The beads were then washed six times with 300 µl of HNT. Precipitations at 50 mM NaCl were carried out at this salt
level in both the binding and the wash steps. All other samples were
bound at 100 mM NaCl, and the salt was adjusted between 100 and 400 mM
in the wash buffers. snRNAs bound to the antibody matrix were released by the addition of 100 µl of 1× PK buffer (100 mM Tris-HCl [pH 7.5], 12.5 mM EDTA, 150 mM NaCl, 1% sodium dodecyl sulfate, 2 mg of
proteinase K/ml) for 10 min at 37°C. The samples were phenol extracted and precipitated with ethanol prior to Northern blot analysis
with the previously described snRNA probe set (5). Glycerol
gradients (10 to 35%) were run and assayed for snRNA content by immune
precipitation as previously described (25). Approximately
150 µl (20 mg of protein content/ml) of total extract protein was
resolved and separated into 22 fractions of 0.5 ml each. One-third of
each fraction was either assayed directly for snRNA content or
precipitated with the HA.11 antibody and then scored for snRNA.
Western blotting was performed on 60 µg of total extract protein
resolved on a 10 or 12% discontinuous polyacrylamide gel
prepared with
a 4% stacking phase. Proteins were electroblotted
to an Immobilon P
membrane (Millipore) in a mini-V 8-10 apparatus
(Gibco/BRL) with
transfer buffer (24.8 mM Tris-HCl-192 mM glycine)
adjusted to 10%
(vol/vol) with methanol. Immune detection was
carried out with the
anti-HA antibody HA.11 (Babco) diluted 1:1,500
in phosphate-buffered
saline containing 5% nonfat dry milk. The
secondary antibody was a
goat anti-mouse immunoglobulin G (heavy
and light chains)-alkaline
phosphatase conjugate (Gibco/BRL) developed
with the
5-bromo-4-chloro-3-indolylphosphate (BCIP)-nitroblue
tetrazolium
chloride (NBT) chromogenic substrate mixture as recommended
by the
supplier (Gibco/BRL).
 |
RESULTS |
Selection of prp38-1 dosage suppressors.
A yeast
genomic library based on the high-copy-number plasmid YEp13 was used to
select plasmids that reduced the temperature-sensitive growth defect
caused by the prp38-1 mutation in yeast strain ts192 (5). From approximately 20,000 yeast transformants, 11 that showed plasmid-dependent colony formation at 37°C were identified. DNA restriction site analysis and hybridization studies on the recovered plasmids revealed that three distinct types of genomic inserts were recovered. Plasmids with type-A inserts (e.g., YEp13-2) or
type-B inserts (e.g., YEp13-7) relieved the prp38-1 growth defect with high efficiency, while plasmids with type-C inserts (e.g.,
YEp13-5) suppressed it much more weakly (Fig.
1). The wild-type allele of
PRP38 was present in both of the identified type-A plasmids. DNA sequence analysis showed that the type-C insert DNA was not present
in the published yeast genome database or in other publicly held
databases. Plasmids of categories A and C were not studied further.

View larger version (84K):
[in this window]
[in a new window]
|
FIG. 1.
Identification of dosage suppressors of the Ts
prp38-1 mutation. Yeast cultures were streaked on
nonselective medium and incubated at 23 and 37°C. The colony sizes of
the untransformed prp38-1 mutant and wild-type
(PRP38) yeast strains are compared with those of the
prp38-1 mutant transformed with the indicated multi-copy
plasmids. The plasmids encoded a functional PRP38 gene
(YEp13-2), a weak suppressor of prp38-1 (YEp13-5), or an
efficient suppressor of prp38-1 (YEp13-7 and
YEplac112-7A).
|
|
Each of the seven type-B plasmids contained identical or overlapping
regions of the right arm of yeast chromosome II. Two
genes of defined
function,
RPB5 and
RIB7, were present in these
library segments.
RPB5 encodes the 27-kDa subunit common to
the
three nuclear RNA polymerases (
44).
RIB7
encodes an activity
required for riboflavin biosynthesis
(
7). Besides these genes,
two uncharacterized ORFs, YBR151w
and YBR152w, were present. Of
these, YBR152w had the capacity to code
for a small acidic protein
(Fig.
2).
Embedded within its amino terminus are two serine-rich
elements similar
to a sequence found in the carboxyl terminus
of the Prp38p protein
(
5). The second of the YBR152w-encoded
serine-rich elements
contains an exceptionally strong match to
the PEST protein degradation
signal (amino acids 56 through 95).
Prp38p does not contain the PEST
motif. YBR152w was subcloned
free of the adjacent genes and assayed for
suppression in the
high-copy-number shuttle vector YEplac112
(
13). The YEplac112-7A
subclone efficiently suppressed the
ts192 temperature-sensitive
growth defect, confirming that YBR152w
contained the suppressor
activity (Fig.
1). This dosage suppressor of
prp38-1 was renamed
SPP381, for suppressor of
prp38-1.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Predicted amino acid sequence encoded by ORF YBR152w
(SPP381). The acidic serine-rich elements common to Prp38p
and Spp381p are underlined. The putative PEST sequence is represented
by bold italics. Spp381p has a predicted molecular mass of 33.8 kDa and
a predicted pI of 5.4. In comparison, Prp38p is a 28-kDa protein with a
predicted pI of 5.0 (5).
|
|
Suppression by
SPP381 is gene restricted, as evidenced by
the fact that library plasmid YEp13-7 did not relieve the Ts growth
defects of randomly selected
prp2,
prp5,
prp11,
prp9,
prp17,
prp19,
prp20, or
prp39 mutants. Conceivably, elevated
Spp381p levels
might influence the abundance, localization, or activity
of the
Prp38-1p protein. Alternatively, the increased abundance of
Spp381p
may bypass the cellular requirement for Prp38p. The latter
possibility
was ruled out with the demonstration that
SPP381
on plasmid YEplac112-7A
did not suppress a
prp38::LEU2 null allele (reference
35) (data
not shown). Thus, enhanced expression of
SPP381 supports, but
does not supplant,
PRP38 activity.
Efficient pre-mRNA splicing is restored by enhanced
SPP381 expression.
A Northern blot of cellular RNA was
used to score for the impact of plasmid-borne SPP381
expression on pre-mRNA splicing efficiency (Fig.
3). The RP51A
pre-mRNA-to-mRNA ratio of the wild-type parental strain was compared
with that of the untransformed prp38-1 mutant and the
prp38-1 mutant transformed with various suppressor plasmid constructs. RNA was extracted from cultures grown continuously at the
permissive temperature of 23°C and from cultures shifted to the
restrictive temperature of 37°C for 2.5 h. When assayed at the
permissive temperature, all cultures showed abundant amounts of spliced
RP51A mRNA and little pre-mRNA (Fig. 3, lanes 1 to 7). In
contrast, the pre-mRNA/mRNA ratio increased greatly with the
temperature shift in the untransformed mutant (Fig. 3, lane 13) and in
mutants transformed with the weak suppressor (lane 9) or a randomly
chosen library plasmid (lane 12). Plasmid-based expression of the
wild-type PRP38 gene (Fig. 3, lane 8) or enhanced expression
of SPP381 (lanes 10 and 11) decreased the pre-mRNA/mRNA ratio in the mutant strain to near-wild-type levels (lane 14). By this
measure, enhanced SPP381 expression reverses the pre-mRNA processing defect caused by the prp38-1 mutation.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 3.
Influence of suppressor gene expression on cellular
pre-mRNA splicing. RNA was isolated from the indicated yeast cultures
grown continuously at 23°C and after a 2-h shift to 37°C. The
hybridization probe consisted of exon and intron sequences of the yeast
RP51A gene, and the positions of pre-mRNA (P) and mRNA (M)
are noted. The cultures were from untransformed wild-type yeast
(PRP38), the untransformed mutant strain ts192
(prp38-1), and the prp38-1 mutant after
transformation with the indicated plasmids containing the
PRP38 gene (YEp13-2), a weak suppressor of
prp38-1 (YEp13-5), or an efficient suppressor of ts192
(YEp13-7 and YEplac112-7A). Plasmid YEp13-R was a negative-control
plasmid from the YEp13 library that did not suppress the
prp38-1 mutation.
|
|
SPP381 is an important but not an essential gene for
normal yeast growth.
The SPP381 gene was disrupted by
replacement of approximately 90% of its coding sequence with the
LEU2 selectable marker. When diploid yeast cells
heterozygous for this mutation were sporulated, equal numbers of
colonies of two distinct sizes were observed in the meiotic offspring.
PCR and Southern blot analyses showed that colonies visible after 2 days of incubation on the tetrad dissection plate all possessed the
uninterrupted SPP381 allele. Yeast cells that formed visible
colonies only after 6 to 7 days of incubation all possessed the
spp381::LEU2 disruption. In liquid medium, the
generation time of the spp381::LEU2 disruptant
cultures was approximately seven times that of the wild-type siblings
(10 to 11 versus 1.75 h). This mutant was not obviously heat or
cold sensitive, as colony formation appeared equivalently poor at 17, 23, and 37°C compared with that of the SPP381 strain (Fig.
4 and data not shown). The limited
SPP381 coding sequence still present in this strain did not
contribute to the viability of this mutant, since a disruptant in which
HIS3 replaced all sequences between the SPP381
translational initiation and termination codons showed equivalent
results (10a). In both cases, the
spp381::LEU2 slow-growth defect was specifically
reversed by expression of the SPP381 ORF from the
GAL1 promoter as an HA fusion construct
(GAL1::SPP381HA) (Fig. 4 and data not shown).
Given the approximate sevenfold decrease in the growth rate observed
for the spp381::LEU2 mutant, SPP381 is
clearly an important, albeit not an essential, gene in yeast. Deletion
of the putative PEST motif from GAL1::SPP381HA (or
from SPP381) greatly reduced its ability to complement
spp381::LEU2, although such strains did grow
slightly better than the mutant bearing the null allele alone (Fig. 4).
Thus, the proposed PEST sequence contributes to Spp381p biological
activity in vivo.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of growth in SPP381 and
spp381::LEU2 mutant yeast cells. Yeast cultures
were grown to saturation in nonselective broth with 2% galactose. Each
strain was adjusted to a culture density at 600 nm of 0.150. The
presence of equivalent cell numbers in each culture was confirmed
microscopically. Serial 10-fold dilutions (positions 1 to 4) were
spotted in 5-µl volumes on galactose-containing agar medium and
incubated for 4 days at 30°C. The strains used were the wild-type
parent (SPP381), the untransformed
spp381::LEU2 mutant, and the
spp381::LEU2 mutant transformed with the
GAL1::SPP381HA fusion gene or its
PEST-HA derivative.
|
|
Spp381p contributes to cellular pre-mRNA splicing.
A direct
contribution of Spp381p to pre-mRNA splicing might underlie the genetic
interaction between prp38-1 and SPP381. To address this, RNA samples isolated from a wild-type strain and from the
spp381::LEU2 disruptant strain were analyzed by
Northern blotting (Fig. 5). Indicative of
decreased splicing efficiency, yeast with the
spp381::LEU2 disruption showed a greatly elevated ratio of RP51A pre-mRNA to mRNA (Fig. 5A, lane 5) compared
with the wild-type strain (Fig. 5A, lanes 1 and 2). Primer extension carried out with an RP51A exon II primer showed that most of
this intron-bearing RNA was pre-mRNA rather than lariat intermediate, indicating that splicing was inhibited before 5' splice site cleavage. As a control for the specificity, a spp381::LEU2
strain transformed with the GAL1::SPP381HA fusion
gene was assayed in parallel. The spp381::LEU2
splicing defect was specifically reversed by
GAL1::SPP381HA under conditions that induced
transcription of this fusion gene (i.e., growth on galactose). Similar
to what has been reported for other splicing factors (see references
21 and 25 and references therein), splicing was inhibited 10 to 15 h after transcriptional repression of GAL1::SPP381HA (Fig. 5A, lanes 3 and
4, and data not shown). While results with the CYH2 gene
were somewhat less pronounced, transcripts of the CYH2 gene
also showed decreased levels of mRNA and increased levels of pre-mRNA
in the spp381::LEU2 mutant background (Fig. 5B).
The more modest CYH2 defect suggests that not all introns
are equally dependent upon Spp381p protein for excision. We note also
that, compared with RP51A, the splicing of CYH2
precursors was somewhat less sensitive to Prp38-1p temperature inactivation (Fig. 5A and B, lanes 7 and 8). No reproducible changes with the intronless ADE3 mRNA, rRNA, or
trimethylguanosine-capped snRNAs were associated with the
spp381::LEU2 mutation (Fig. 5C) (unpublished
data). Thus, the growth impediment of the
spp381::LEU2 mutant can be accounted for by
decreased pre-mRNA splicing efficiency in the absence of Spp381p.
Unlike the prp38-1 mutation, the
spp381::LEU2 splicing defect was not suppressed by
overexpression of PRP38 on a high-copy-number plasmid or as
a GAL1::PRP38 fusion gene. Together, these data
provide strong evidence that PRP38 and SPP381 make important and independent contributions to cellular pre-mRNA splicing.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 5.
Contribution of SPP381 to the efficiency of
pre-mRNA splicing in vivo. RNA was isolated from wild-type yeast (lanes
1 and 2) and the spp381::LEU2 disruptant before
(lane 5) and after transformation with
GAL1::SPP381HA (lanes 3 and 4) or with
GAL1::spp381 PEST-HA (lane 6). Galactose (gal)
or glucose (glu) was used to activate or repress the GAL1
fusion constructs as indicated. Lanes 7 to 12, RNA from the
untransformed prp38-1 mutant (lanes 7 and 8) and the same
strain after transformation with the high-copy-number (i.e., YEp112)
plasmid bearing SPP381 (lanes 9 and 10) or its
PEST (YEplac112-based) derivative (lanes 11 and 12). The
RNA was recovered from cultures grown continuously at the permissive
temperature for prp38-1 (23°C) or after 2.5 h at the
restrictive temperature (37°C). The positions of pre-mRNA (P) and
spliced mRNA (M) are indicated by arrowheads. (A) Hybridization with an
RP51A-specific intron-plus-exon probe. (B) Hybridization
with a CYH2-specific intron-plus-exon probe. (C)
Hybridization with an ADE3 gene body probe.
|
|
Yeast that expressed
GAL1::
PEST-HA spliced
RP51A pre-mRNA poorly (Fig.
5A and B, lanes 6) consistent
with its weak complementation
of the
spp381::LEU2
mutation. Curiously, however, the high-copy-number

PEST construct
continued to suppress the temperature-dependent
splicing defect of the
prp38-1 mutant (Fig.
5A and B, lanes 7
to 12). Thus, Spp381p
retained an aspect of its biological activity
even in the absence of
the PEST sequence. In addition, the splicing
deficiency of
PEST suggests that Spp381p may contribute to splicing
through a step independent of its proposed interaction with
Prp38p.
Spp381p is found in the U4/U5.U6 tri-snRNP particle.
Prp38p is
one of a small group of proteins uniquely associated with the U4/U6.U5
tri-snRNP particle (45). Immune precipitation was used to
determine whether the genetically interacting protein, Spp381p, was
likewise associated with snRNP. In all extracts tested, the total
(i.e., unfractionated) snRNA levels were equivalent (Fig.
6, lanes 1 and 12 to 14). Extracts
prepared from the GAL1::SPP381HA and control
strains were incubated with the anti-HA antibody HA.11 or with the
irrelevant control antibody mAb63. A Northern blot of the immune
pellets washed at 100 mM NaCl revealed that, as with Prp38HAp (Fig. 6,
lane 9), the U4, U5, and U6 snRNAs specifically coprecipitated with
Spp381HAp (lane 4). In contrast, U1 snRNA was recovered with the
HA-tagged U1 snRNP protein, Prp39p (Fig. 6, lane 10). The snRNA
precipitation with Spp381HAp was salt sensitive; the levels of U4, U5,
and U6 snRNAs were greatly reduced at 150 mM NaCl (Fig. 6, lanes 3 to
8). Nevertheless, the U4, U5, and U6 snRNA recovery was specific, as
evidenced by the fact that almost no U-snRNAs were recovered at 100 mM
NaCl from an untagged extract (Fig. 6, lane 11) or when the irrelevant
monoclonal antibody, mAb63, was used with the
GAL1::SPP381HA extract (lane 2). The lower
level of snRNA recovery with the Prp38HAp extract (compared with
that observed for Spp381HAp) may reflect a lower Prp38HAp abundance or
reduced antibody accessibility. This was not due to a lower affinity of
Prp38HAp for the U4/U6.U5 particle, however, as this interaction is
stable to at least 200 mM NaCl (45).

View larger version (81K):
[in this window]
[in a new window]
|
FIG. 6.
Coprecipitation of snRNA with HA-tagged proteins.
Extracts of untagged yeast (lanes 11 and 14) and HA-tagged Spp381HAp
(lanes 1 to 8), Prp38HAp (lanes 9 and 12), and Prp39HAp (lanes 10 and
13) were immune precipitated with the HA-specific antibody HA.11 (lanes
3 to 10) or the irrelevant antibody mAb63 (lane 2). The immune pellets
were fractionated on a denaturing 5% polyacrylamide gel and
transferred to a membrane, and the blot was hybridized with probes
specific for the spliceosomal snRNAs (indicated by arrowheads). Immune
pellets in lanes 3 to 8 were washed with buffer containing the
indicated levels of NaCl; all other pellets were washed with buffer
adjusted to 100 mM NaCl. For comparison of relative snRNAs,
nonprecipitated extract RNAs (Total) were resolved in parallel (lanes 1 and 12 to 14).
|
|
Based on the immune precipitation results, it appeared that Spp381p was
present in the U4/U6.U5 tri-snRNP particle. This prediction
was tested
by glycerol gradient fractionation of the Spp381HAp
splicing extract
(Fig.
7). As described previously
(
6,
45),
this fractionation technique resolves the free U6
snRNP particles
(Fig.
7A, fractions 6 to 10) and free U5 snRNP
particles (Fig.
7A, fractions 12 and 14) from the U4/U6.U5 tri-snRNP
particles
(fractions 16 and 18). The U4, U5, and U6 snRNAs
coprecipitate
efficiently with the HA.11 antibody only from the
tri-snRNP fractions
(Fig.
7B, fractions 16 and 18), even though both U6
and U5 are
abundantly present elsewhere in the gradient. The
cofractionation
and coprecipitation results provide clear evidence for
Spp381HAp
association with the U4/U6.U5 tri-snRNP particle.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 7.
Cofractionation of Spp381HAp with the U4/U6.U5 tri-snRNP
particle. The yeast splicing extract was fractionated on a linear 10 to
35% glycerol gradient. (A) Even-numbered fractions were assayed by
Northern blotting for the presence of U5 (the long and short forms, U5L
and U5S, respectively), U4, and U6 snRNA. (B) Spp381HAp was immune
precipitated from the fractions presented in panel A with the anti-HA
antibody HA.11 and was assayed for coassociated snRNAs by Western
blotting with the same antibody.
|
|
Prp38p and Spp381p interact in vivo.
The dosage suppression
and snRNA precipitation studies showed that Spp381p and Prp38p interact
genetically and associate with the same biochemical complex. A
two-hybrid analysis was next performed to investigate the possibility
that these two proteins associate directly. Simultaneous expression of
Spp381p and Prp38p as Gal4 fusion products led to strong
transactivation of the lacZ and HIS3 reporter
genes in the host strain (Table 1 and
data not shown). A Spp381-Gal4 binding domain plasmid did not
transactivate when paired with an empty activation domain vector or
when the PRP38 DNA was inserted in the reverse orientation.
As a first step in assessing the domain structure of the Spp381p and
Prp38p molecules, fusion constructs consisting of the amino- and
carboxyl-terminal halves were used for two-hybrid analysis. For unknown
reasons, activation domain-independent stimulation with
Spp381p(146-291) was about twofold greater than that observed with
full-length Spp381p. Nevertheless, sequences necessary and sufficient
for the Prp38p interaction clearly reside in the Spp381p carboxyl terminus, since Spp381p(146-291) and Spp381p(1-291) stimulated Prp38p-dependent transactivation to similar levels. In contrast, Spp381p amino acids 1 to 145 failed to interact with Prp38p. Thus, the
putative PEST sequence, although important for the Spp381p function in
splicing, is not required for interaction with Prp38p. Spp381p(146-291) did not interact with Prp38p(1-121) or
Prp38p(122-242), suggesting that the interacting domain may comprise
(or span) both halves of Prp38p. Supporting evidence for a critical
N-terminal interaction was provided by the observation that either of
two Ts mutations in this region, G66D (prp38-1) and C87Y
(prp38-2), greatly reduced the level of transactivation with
Spp381p(1-291). Overall, the two-hybrid results support an interaction
between the carboxyl terminus of Spp381p and one or more regions of
Prp38p.
The Spp381HAp fusion protein has a predicted molecular size of
approximately 35 kDa. On polyacrylamide gels, however, Spp381HAp
migrates as a 51-kDa protein (Fig.
8,
lanes 1 and 2). This anomalous
migration might be caused by the highly
acidic amino terminus
of this protein, which also contains numerous
possible sites for
phosphorylation. Consistent with this, removal of
the 4.6-kDa
PEST sequence deletion caused an apparent 13-kDa shift to
produce
a protein with an apparent mass of 38 kDa (Fig.
8, lanes 4 and
5; predicted mass, 30.3 kDa). Equivalent amounts of the Spp381HAp
and

PEST-HAp derivatives accumulated in cells when expressed
from the
GAL1 promoter, indicating that under these conditions
the
PEST sequence contributes little to stability. Curiously,
given
the importance of Spp381p to in vivo splicing, extracts
prepared
from the glucose-depleted
GAL1::SPP381HA culture (Fig.
8, lane 3) were found to splice
RP51A pre-mRNA through both
chemical
steps in vitro (data not shown). Thus, it appears that either
Spp381p is not required in vitro, or it contributes to an activity
not
assayed under typical in vitro splicing conditions (see Discussion).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 8.
Identification of Spp381HAp. Sixty micrograms of yeast
extract protein was resolved on 12% (lanes 1 to 3) and 10% (lanes 4 and 5) polyacrylamide gels. A Western blot from each gel was hybridized
with the anti-HA antibody HA.11 to reveal the presence of Spp381HAp and
its PEST-HAp derivative (indicated by asterisks). Numbers on the
left and right show the positions of protein molecular weight markers
(mid-range; Promega) run in adjacent lanes. The extracts assayed
included an untagged yeast strain (lane 1), a
GAL1::SPP381HA strain grown continuously in
galactose (lanes 2 and 5) or shifted to a glucose-based medium for
18 h (lane 3), and extract prepared from the
GAL1:: PEST-HA derivative (lane 4).
|
|
 |
DISCUSSION |
Prp38p was recently shown to be necessary for dissociation of the
U4/U6 intermolecular helices (45), an essential maturation step that occurs prior to pre-mRNA 5' splice site cleavage. In this
study, we used the genetic approach of dosage suppression to identify a
novel protein, Spp381p, that contributes to Prp38p function in
splicing. The genetic and biochemical evidence indicates that Spp381
and Prp38p define a novel class of interacting acidic proteins which
promote U4/U6.U5 tri-snRNP activity in the spliceosome cycle.
Multiple models for dosage suppression have been described based on
kinetic or thermodynamic contributions of the overexpressed gene
product to the process under study (for instance, see references 20 and 32). The fact that extra
copies of SPP381 do not suppress a
prp38::LEU2 null allele shows convincingly that
increased Spp381p levels do not bypass the need for Prp38p in splicing.
In principle, the elevated abundance of Spp381p might increase the
stability or residual activity of the temperature-sensitive
prp38-1 gene product. The latter suggestion appears more
likely, since under a variety of conditions, we find no evidence for
increased Prp38-1p abundance with enhanced Spp381p expression
(unpublished data). While this result and the positive two-hybrid data
are consistent with direct contact between Prp38p and Spp381p, we
cannot rule out the possibility that a third component mediates this
interaction. However, in the absence of data supporting a such a third
factor, we favor the view that the genetic suppression occurs due to an increased frequency of Spp381p interaction with a functionally impaired
Prp38-1p protein. An Spp381p-Prp38-1p interaction may promote a
favorable structural change within Prp38-1p to facilitate the binding
of Prp38-1p to the U4/U6.U5 tri-snRNP, promote Prp38-1 interaction with
other splicing components, or in some other manner enhance the activity
of the essential Prp38p protein.
Since Prp38p appears to be exclusively a U4/U6.U5 tri-snRNP protein
(45), it is likely within this particle that Spp381p normally contacts Prp38p. Previously, two uncharacterized proteins similar to Spp381p in size were reported in the yeast tri-snRNP (11). Glycerol gradient fractionation of yeast snRNP
complexes presented here demonstrates the presence of Spp381HAp in the
U4/U6.U5 tri-snRNP particle and the absence of antibody-accessible
Spp381HAp in the free U5 or free U6 snRNP complexes. It remains
possible, however, that Spp381HAp binds to the low-abundance U4/U6
di-snRNP precursor (19, 23, 26) or is present in an
antibody-inaccessible form in other snRNP complexes. Both the
two-hybrid results presented here and the presence of Spp381HAp in an
immune pellet prepared with an anti-Prp38p antibody (32)
support the view that Spp381p and Prp38p are ubiquitous (as opposed to
alternative) components of the U4/U6.U5 tri-snRNP particle. Prp38p and
Spp381p are clearly "weakly associated" snRNP proteins, similar in
salt sensitivity to the phylogenetically conserved SF3a proteins of the
17S U2 snRNP (reference 3; see also references in
reference 19), U1C (39), U1-Prp42p
(25), and Prp38p tri-snRNP protein (45). No clear
counterpart to Spp381p is known in mammals, although at least one
small, highly charged phosphoprotein is a component of the mammalian
U4/U6.U5 tri-snRNP particle (12).
What is the role of Spp381p in splicing? In vivo, enhanced
SPP381 expression relieves the block to pre-mRNA 5' splice
site cleavage imposed by the loss of Prp38p function. This observation suggests that Spp381p contributes to snRNP rearrangement events that
lead to the catalytic activation of the spliceosome. Consistent with
this, deletion of the SPP381 gene severely impairs yeast growth and inhibits step 1 in splicing. Surprisingly, we have not
detected in vitro splicing defects in extracts prepared from glucose-repressed GAL1::SPP381HA cultures. U4
snRNA is released from the spliceosome, and both chemical steps in
splicing occur unimpeded. Since SPP381 affects the
efficiency (but not the absolute occurrence) of splicing in vivo, the
lack of an obvious in vitro defect may indicate that Spp381p function
is not rate limiting for the comparatively slow in vitro reaction.
Alternatively, Spp381p function may be important in vitro but its
function may not be obvious under standard assay conditions. Ample
precedent exists for such behavior by splicing factors. For instance,
extracts deficient in Prp22p, Prp24p, or Prp43p can correctly process
pre-mRNA through both chemical steps in splicing but are defective in
postsplicing steps of mRNA release (Prp22p
[10]), U4/U6 snRNA reanealing (Prp24p
[30, 42]), and intron release (Prp43p
[1]). The spliceosomal precursor pool in the
Spp381HAp-depleted culture is an unknown and may increase by
the release of endogenous spliceosomes during the 8-h extract
preparation protocol. If Spp381p acts as a recycling or dissociation
factor, its importance might not be obvious until the spliceosomal
precursors become saturated with, or depleted of, the exogenously added
pre-mRNA, as shown for Prp24p (30).
It is well established that the removal of a PEST sequence can greatly
increase the half-life of an unstable protein (e.g., c-Fos
[40]) and that the transfer of a PEST sequence to a
naturally stable protein can greatly enhance its turnover (e.g.,
dihydrofolate reductase [22]; see references
31 and 33 for additional examples
of PEST-mediated destabilization). Proteins with functionally defined
PEST elements often have PEST values in the range of 4 to 16 (e.g.,
yeast Gcn4, mammalian Fos, ornithine decarboxylase, Aspergillus NIMA). The 40-amino-acid Spp381p element has a
PEST sequence value of +29.8 and ranks higher than all of the 99 PEST elements presented in two recent reviews (2, 31). The
presence of a PEST sequence raises the interesting possibility that
proteolysis of Spp381p triggers a particular event of the spliceosome
cycle. Many PEST-mediated proteolysis events are regulated
(31). Perhaps the most obvious role for proteolysis would be
to promote spliceosome disassembly following pre-mRNA splicing. A
spliceosome-dependent turnover would explain the similar intracellular
levels of Spp381HAp and its
PEST-HA derivative when these proteins
are overexpressed (beyond the needs of splicing) by the GAL1
promoter. Intriguingly, while uncommon in spliceosomal proteins, the
DExD/H-box proteins Prp22p, Prp28p, Brr2p, Prp43p, and Prp16p all
possess good fits to the PEST consensus (PEST scores of 14.5, 13.4, 11.3, 7.3, and 5.7, respectively). Although highly speculative, it is
conceivable that PEST sequence-mediated modification (i.e.,
phosphorylation or proteolysis subsequent to function rather than
dissociation accounts for the "transient" association of members of
this group with the spliceosome (see reference 38).
Experiments are under way to define the function of Spp381p in splicing
and to test the possibility that proteolysis contributes to the
spliceosome cycle.
 |
ACKNOWLEDGMENTS |
We thank Frances McFarland, Martha Peterson, John Woolford, and
our lab colleagues Seyung Chung, Mitch McLean, and Liz Otte for their
helpful comments on the manuscript.
This work was supported by an HHMI summer support fellowship to V.B.
and by National Institutes of Health grant GM42476 (to B.C.R.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: T. H. Morgan School of Biological Sciences and The Markey Cancer Center,
University of Kentucky, Lexington, KY 40506-0225. Phone: (606)
257-5530. Fax: (606) 257-1717. E-mail: rymond{at}pop.uky.edu.
Present address: Department of Biology, University of Michigan, Ann
Arbor, MI 48109-1048.
 |
REFERENCES |
| 1.
|
Arenas, J. E., and J. N. Abelson.
1997.
Prp43: an RNA helicase-like factor involved in spliceosome disassembly.
Proc. Natl. Acad. Sci. USA
94:11798-11802[Abstract/Free Full Text].
|
| 2.
|
Barnes, J. A., and A. V. Gomes.
1995.
PEST sequences in calmodulin-binding proteins.
Mol. Cell. Biochem.
149/150:17-27.
|
| 3.
|
Behrens, S.-E.,
K. Tyc,
B. Kaster,
J. Reichelt, and R. Lührmann.
1993.
Small nuclear ribonucleoprotein (RNP) U2 contains numerous additional proteins and has a bipartite RNP structure under splicing conditions.
Mol. Cell. Biol.
13:307-319[Abstract/Free Full Text].
|
| 3a.
| Beickman, K., and B. C. Rymond. Unpublished
data.
|
| 4.
|
Berben, G.,
J. Dumont,
V. Gilliquet,
P.-A. Bolle, and F. Hilger.
1991.
The YDp plasmids: a uniform set of vectors bearing versatile gene disruption cassettes for Saccharomyces cerevisiae.
Yeast
7:475-477[Medline].
|
| 5.
|
Blanton, S.,
A. Srinivasan, and B. C. Rymond.
1992.
PRP38 encodes a yeast protein required for pre-mRNA splicing and maintenance of stable U6 small nuclear RNA levels.
Mol. Cell. Biol.
12:3939-3947[Abstract/Free Full Text].
|
| 6.
|
Bordonne, R.,
J. Banroques,
J. Abelson, and C. Guthrie.
1990.
Domains of yeast U4 spliceosomal RNA required for PRP4 protein binding, snRNP-snRNP interactions, and pre-mRNA splicing in vivo.
Genes Dev.
4:1185-1196[Abstract/Free Full Text].
|
| 7.
|
Buitrago, M. J.,
G. A. Gonzalez,
J. E. Saiz, and J. L. Revuelta.
1993.
Mapping of the RIB1 and RIB7 genes involved in the biosynthesis of riboflavin in Saccharomyces cerevisiae.
Yeast
9:1099-1102[Medline].
|
| 8.
|
Burgess, S. M., and C. Guthrie.
1993.
Beat the clock: paradigms for NTPases in the maintenance of biological fidelity.
Trends Biochem. Sci.
18:381-834[Medline].
|
| 9.
|
Cheng, S.-C., and J. Abelson.
1987.
Spliceosome assembly in yeast.
Genes Dev.
1:1014-1027[Abstract/Free Full Text].
|
| 10.
|
Company, M.,
J. Arenas, and J. Abelson.
1991.
Requirement of the RNA helicase-like protein PRP22 for release of messenger RNA from spliceosomes.
Nature
349:487-493[Medline].
|
| 10a.
| Dembla-Rajpal, N., and B. C. Rymond.
Unpublished data.
|
| 11.
|
Fabrizio, P.,
S. Esser,
B. Kastner, and R. Lührmann.
1994.
Isolation of S. cerevisiae snRNPs: comparison of U1 and U4/U6.U5 to their human counterparts.
Science
264:261-265[Abstract/Free Full Text].
|
| 12.
|
Fetzer, S.,
J. Lauber,
C. L. Will, and R. Lührmann.
1997.
The U4/U6.U5 tri-snRNP-specific 27K protein is a novel SR protein that can be phosphorylated by the snRNP-associated protein kinase.
RNA
3:344-355[Abstract].
|
| 13.
|
Gietz, R. D., and A. Sugino.
1988.
New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites.
Gene
74:527-534[Medline].
|
| 14.
|
Johnston, M., and R. W. Davis.
1984.
Sequences that regulate the divergent GAL1-GAL10 promoter in Saccharomyces cerevisiae.
Mol. Cell. Biol.
4:1440-1448[Abstract/Free Full Text].
|
| 15.
|
Kaiser, C.,
S. Michaelis, and A. Mitchell.
1994.
Methods in yeast genetics.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 16.
|
Kim, S.-H., and R.-J. Lin.
1993.
Pre-mRNA splicing within an assembled yeast spliceosome requires an RNA-dependent ATPase and ATP hydrolysis.
Proc. Natl. Acad. Sci. USA
90:888-892[Abstract/Free Full Text].
|
| 17.
|
Kim, S.-H., and R.-J. Lin.
1996.
Spliceosome activation by PRP2 ATPase prior to the first transesterification reaction of pre-mRNA splicing.
Mol. Cell. Biol.
16:6810-6819[Abstract].
|
| 18.
|
Konarska, M. M., and P. A. Sharp.
1987.
Interactions between small nuclear ribonucleoprotein particles in formation of spliceosomes.
Cell
49:763-774[Medline].
|
| 19.
|
Krämer, A.
1996.
The structure and function of proteins involved in mammalian pre-mRNA splicing.
Annu. Rev. Biochem.
65:367-409[Medline].
|
| 20.
|
Last, R. L.,
J. R. Maddock, and J. L. Woolford, Jr.
1987.
Evidence for related functions of the RNA genes of Saccharomyces cerevisiae.
Genetics
117:619-631[Abstract/Free Full Text].
|
| 21.
|
Lockhart, S., and B. C. Rymond.
1994.
Commitment of yeast pre-mRNA to the splicing pathway requires a novel U1 small nuclear ribonucleoprotein polypeptide, Prp39p.
Mol. Cell. Biol.
14:3623-3633[Abstract/Free Full Text].
|
| 22.
|
Loetscher, P.,
G. Pratt, and M. Rechsteiner.
1991.
The C terminus of mouse ornithine decarboxylase confers rapid degradation on dihydrofolate reductase. Support for the PEST hypothesis.
J. Biol. Chem.
266:11213-11220[Abstract/Free Full Text].
|
| 23.
|
Madhani, H. D., and C. Guthrie.
1994.
Dynamic RNA-RNA interactions in the spliceosome.
Annu. Rev. Genet.
28:1-26[Medline].
|
| 24.
|
Matsuoka, S.,
M. C. Edwards,
C. Bai,
S. Parker,
P. Zhang,
A. Baldini,
J. W. Harper, and S. J. Elledge.
1995.
P57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Genes Dev.
9:650-662[Abstract/Free Full Text].
|
| 25.
|
McLean, M. R., and B. C. Rymond.
1998.
Yeast pre-mRNA splicing requires a pair of U1 snRNP-associated tetratricopeptide repeat proteins.
Mol. Cell. Biol.
18:353-360[Abstract/Free Full Text].
|
| 26.
|
Moore, M. J.,
C. C. Query, and P. A. Sharp.
1993.
Splicing of precursors to mRNA by the spliceosome, p. 303-358.
In
R. F. Gesteland, and J. F. Atkins (ed.), The RNA world. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 27.
|
O'Day, C. L.,
G. Dalbadie-McFarland, and J. Abelson.
1996.
The Saccharomyces cerevisiae Prp5 protein has RNA-dependent ATPase activity with specificity for U2 small nuclear RNA.
J. Biol. Chem.
271:33261-33267[Abstract/Free Full Text].
|
| 28.
|
Pikielny, C. W., and M. Rosbash.
1986.
Specific small nuclear RNAs are associated with yeast spliceosomes.
Cell
45:869-877[Medline].
|
| 29.
|
Pikielny, C. W.,
B. C. Rymond, and M. Rosbash.
1986.
Electrophoresis of ribonucleoproteins reveals an ordered assembly of yeast splicing complexes.
Nature
324:341-345[Medline].
|
| 30.
|
Raghunathan, P. L., and C. Guthrie.
1998.
A spliceosome recycling factor that reanneals U4 and U6 small nuclear ribonucleoprotein particles.
Science
279:857-860[Abstract/Free Full Text].
|
| 31.
|
Rechsteiner, M., and S. W. Rogers.
1996.
PEST sequences and regulation by proteolysis.
Trends Biochem. Sci.
21:267-271[Medline].
|
| 32.
|
Rine, J.
1991.
Gene overexpression in studies of Saccharomyces cerevisiae.
Methods Enzymol.
194:239-251[Medline].
|
| 33.
|
Rogers, S.,
R. Wells, and M. Rechsteiner.
1986.
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis.
Science
234:364-386[Abstract/Free Full Text].
|
| 34.
|
Rosbash, M., and B. Seraphin.
1991.
Who's on first? The U1 snRNP-5' splice site interaction and splicing.
Trends Biochem. Sci.
16:187-190[Medline].
|
| 35.
|
Rymond, B. C.
1993.
Convergent transcripts of the yeast PRP38-SMD1 locus encode two essential splicing factors, including the D1 core polypeptide of small nuclear ribonucleoprotein particles.
Proc. Natl. Acad. Sci. USA
90:848-852[Abstract/Free Full Text].
|
| 36.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 37.
|
Schwer, B., and C. Guthrie.
1992.
A conformational rearrangement in the spliceosome is dependent on PRP16 and ATP hydrolysis.
EMBO J.
11:5033-5039[Medline].
|
| 38.
|
Staley, J. P., and C. Guthrie.
1998.
Mechanical devices of the spliceosome: motors, clocks, springs, and things.
Cell
92:315-326[Medline].
|
| 39.
|
Tang, J.,
N. Abovich,
M. L. Fleming,
B. Seraphin, and M. Rosbash.
1997.
Identification and characterization of the yeast homolog of U1 snRNP-specific protein C.
EMBO J.
16:4082-4091[Medline].
|
| 40.
|
Tsurumi, C.,
N. Ishida,
T. Tamura,
A. Kakizuka,
E. Nishida,
E. Okumura,
T. Kishimoto,
M. Inagaki,
K. Okazaki,
N. Sagata,
A. Ichihara, and K. Tanaka.
1995.
Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases.
Mol. Cell. Biol.
15:5682-5687[Abstract].
|
| 41.
|
Umen, J. G., and C. Guthrie.
1995.
A novel role for a U5 snRNP protein in 3' splice site selection.
Genes Dev.
9:855-868[Abstract/Free Full Text].
|
| 42.
|
Vijayraghavan, U.,
M. Company, and J. Abelson.
1989.
Isolation and characterization of pre-mRNA splicing mutants of Saccharomyces cerevisiae.
Genes Dev.
3:1206-1216[Abstract/Free Full Text].
|
| 43.
|
Wang, Y.,
J. D. O. Wagner, and C. Guthrie.
1998.
Prp16, a DEAH-box splicing factor, unwinds RNA duplexes in vitro.
Curr. Biol.
8:441-451[Medline].
|
| 44.
|
Woychik, N. A.,
S. M. Liao,
P. A. Kolodziej, and R. A. Young.
1990.
Subunits shared by eukaryotic nuclear RNA polymerases.
Genes Dev.
4:313-323[Abstract/Free Full Text].
|
| 45.
|
Xie, J.,
K. Beickman,
E. Otte, and B. C. Rymond.
1998.
Progression through the spliceosome cycle requires Prp38p function for U4/U6 snRNA dissociation.
EMBO J.
17:2938-2946[Medline].
|
| 46.
|
Xu, D.,
S. Nouraini,
D. Field,
S. J. Tang, and J. D. Friesen.
1996.
An RNA-dependent ATPase associated with U2/U6 snRNAs in pre-mRNA splicing.
Nature
381:709-713[Medline].
|
| 47.
|
Yean, S.-L., and R.-J. Lin.
1991.
U4 small nuclear RNA dissociates from a yeast spliceosome and does not participate in the subsequent splicing reaction.
Mol. Cell. Biol.
11:5571-5577[Abstract/Free Full Text].
|
Molecular and Cellular Biology, January 1999, p. 577-584, Vol. 19, No. 1
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pandit, S., Lynn, B., Rymond, B. C.
(2006). Inhibition of a spliceosome turnover pathway suppresses splicing defects. Proc. Natl. Acad. Sci. USA
103: 13700-13705
[Abstract]
[Full Text]
-
GRAINGER, R. J., BEGGS, J. D.
(2005). Prp8 protein: At the heart of the spliceosome. RNA
11: 533-557
[Abstract]
[Full Text]
-
Stevens, S. W., Abelson, J.
(1999). Purification of the yeast U4/U6·U5 small nuclear ribonucleoprotein particle and identification of its proteins. Proc. Natl. Acad. Sci. USA
96: 7226-7231
[Abstract]
[Full Text]
-
Awasthi, S., Palmer, R., Castro, M., Mobarak, C. D., Ruby, S. W.
(2001). New Roles for the Snp1 and Exo84 Proteins in Yeast Pre-mRNA Splicing. J. Biol. Chem.
276: 31004-31015
[Abstract]
[Full Text]